Omnicell/$OMCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Ticker
$OMCL
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,620
ISIN
US68213N1090
Website
Omnicell Metrics
BasicAdvanced
$1.4B
65.73
$0.45
0.78
-
Price and volume
Market cap
$1.4B
Beta
0.78
52-week high
$51.85
52-week low
$22.66
Average daily volume
477K
Financial strength
Current ratio
1.382
Quick ratio
1.072
Long term debt to equity
15.887
Total debt to equity
30.692
Interest coverage (TTM)
2.39%
Profitability
EBITDA (TTM)
69.629
Gross margin (TTM)
43.24%
Net profit margin (TTM)
1.87%
Operating margin (TTM)
1.11%
Effective tax rate (TTM)
37.50%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
0.35%
Return on equity (TTM)
1.73%
Valuation
Price to earnings (TTM)
65.727
Price to revenue (TTM)
1.213
Price to book
1.1
Price to tangible book (TTM)
4.1
Price to free cash flow (TTM)
12.812
Free cash flow yield (TTM)
7.81%
Free cash flow per share (TTM)
232.37%
Growth
Revenue change (TTM)
3.00%
Earnings per share change (TTM)
-197.59%
3-year revenue growth (CAGR)
-1.79%
10-year revenue growth (CAGR)
9.57%
3-year earnings per share growth (CAGR)
-32.73%
10-year earnings per share growth (CAGR)
-5.87%
What the Analysts think about Omnicell
Analyst ratings (Buy, Hold, Sell) for Omnicell stock.
Bulls say / Bears say
Omnicell reported third-quarter earnings that surpassed analyst estimates, with adjusted earnings per share of $0.56, beating the consensus of $0.42, and revenue of $282 million, slightly above expectations. (investing.com)
The company raised its full-year 2024 guidance, now expecting non-GAAP earnings per share between $1.65 and $1.72, up from the previous forecast and above the analyst consensus of $1.43. (investing.com)
Wells Fargo & Company upgraded Omnicell's rating from 'Equal-Weight' to 'Overweight' on May 14, 2025, indicating increased confidence in the company's performance. (nasdaq.com)
Zacks Research lowered their FY2027 EPS estimates for Omnicell from $1.36 to $1.22, reflecting concerns about the company's future earnings potential. (marketbeat.com)
Wells Fargo & Company reduced Omnicell's price target from $49.00 to $40.00 in January 2025, indicating a more cautious outlook on the stock. (marketbeat.com)
JPMorgan Chase & Co. decreased their price target for Omnicell from $44.00 to $36.00 and maintained a 'Neutral' rating, suggesting limited upside potential. (webull.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Omnicell Financial Performance
Revenues and expenses
Omnicell Earnings Performance
Company profitability
Omnicell News
AllArticlesVideos
Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program
Business Wire·2 months ago
Omnicell Opens New Innovation Lab in Austin, Texas
Business Wire·2 months ago
Omnicell Announces First Quarter 2025 Results
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omnicell stock?
Omnicell (OMCL) has a market cap of $1.4B as of July 11, 2025.
What is the P/E ratio for Omnicell stock?
The price to earnings (P/E) ratio for Omnicell (OMCL) stock is 65.73 as of July 11, 2025.
Does Omnicell stock pay dividends?
No, Omnicell (OMCL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Omnicell dividend payment date?
Omnicell (OMCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Omnicell?
Omnicell (OMCL) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.